Skip to main content
. 2014 Oct 18;5(22):11564–11575. doi: 10.18632/oncotarget.2595

Figure 3. Co-treatment with paclitaxel and cisplatin led to a reduced tumor growth of NSCLC in mice xenograft model.

Figure 3

(A) (Upper graph) Time course of Id1-GFP-overexpressing (O4) and vector control (P7) xenograft tumor volume with or without treatment of paclitaxel and cisplatin. (Lower graph) Effect of paclitaxel and cisplatin treatment on Id1-GFP-overexpressing (O4) and vector control (P7) xenograft tumor volumes at the end of the xenograft assay. (B) Immunohistochemical staining for the expression of Id1 and p-Akt (Ser473) in xenograft tumors with or without paclitaxel and cisplatin treatment. Original magnification: 200×.